

PHARMACY FACTS

Program Updates from Louisiana Medicaid

March 16, 2022

Provider Enrollment Portal

All providers who file claims with Louisiana Medicaid, including pharmacy providers and immunizing pharmacists, must enroll in the new Medicaid Provider Enrollment Portal **to continue being reimbursed**.

Enrollment is mandated by CMS and applies to any provider that provides care to Medicaid members, which includes current managed care organization (MCO) only providers, Dental Benefits Program Manager (DBPM) providers, Coordinated System of Care (CSoc) providers and existing fee-for-service (FFS) providers. All existing providers must log in and submit an enrollment through the portal at www.lamedicaid.com.

The deadline for provider enrollment is not March 31, 2022. LDH has requested a deadline extension from CMS. The proposed deadline is June 30, 2022 and pending approval from CMS. Louisiana Department of Health, Healthy Louisiana providers are encouraged to take action to complete enrollment. Any existing Medicaid provider that does not complete the enrollment and screening process through the new portal will have their claims denied.

More information is available at www.ldh.la.gov/medicaidproviderenrollment, including previously recorded webinars, a provider manual and frequently asked questions about the portal. If you have further questions about the portal, do not know your Medicaid ID, or do not have your enrollment letter, please email LouisianaProvEnroll@gainwelltechnologies.com or call 833-641-2140, Monday – Friday between the hours of 8 a.m. and 5 p.m. CST.

Fee for Service Dispensing Fee Edit

Effective April 1, 2022, FFS will limit one professional dispensing fee per month per maintenance medication.

The maintenance medication list is posted here:

<https://ldh.la.gov/assets/docs/BayouHealth/Pharmacy/MaintenanceMedications.pdf>.

Upon consultation with the prescriber to verify the necessity of the short fill (quantity less than 30 days' supply), the pharmacist may override the denial by submitting the following override at point of sale (POS):

NCPDP field 420-DK: Submission Clarification Code (SCC) value of 47 – Shortened Days' Supply Fill.

The original claim should be reversed and resubmitted with the SCC override to receive a dispensing fee on the short fill claim. These FFS claims will be subject to audit.

Epogen®/Retacrit®

Pfizer has notified the state of a supply disruption for Retacrit® (EPOETIN ALFA-EPBX), the current preferred product on the Single Preferred Drug List (PDL). Therefore, the Louisiana Department of Health is changing the prior authorization status of Epogen® (EPOETIN ALFA), from non-preferred to preferred status to ensure recipient access. The PDL document will be posted on April 1, 2022 to reflect this change in PA status. Retacrit® will also remain a preferred product.